Welcome to BioSeeker Group!

Triple Analysis: Lung Cancer, Melanoma and Pancreatic Cancer

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3607
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lung Cancer, Melanoma and Pancreatic Cancer in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Melanoma and Pancreatic Cancer.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Melanoma and Pancreatic Cancer.

    To find out more about Triple Analysis: Lung Cancer, Melanoma and Pancreatic Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Melanoma and Pancreatic Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Melanoma and Pancreatic Cancer. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lung Cancer
The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part II: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part III: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lung Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
11 Disclaimer 1300
12 Drug Index 1301
13 Company Index 1314
Figures: Includes 7 Figures
Tables: Includes 284 Tables
Total Number of Pages: 1323

Part II: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part III: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

This Report Includes the Following Companies:
3SBio
A&G Pharmaceutical
AB Science
Abbott
AbbVie
Abiogen
Actelion
Active Biotech
Adherex
Advanced Life Sciences
Advanomics
Advantagene
Advaxis
AEgera
AEterna Zentaris
Agennix
Agenus
Aida Pharmaceuticals
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Allos Therapeutics
Alnylam
AlphaVax
Altor BioScience
Ambit Biosciences
Amgen
AngioChem
Antisense Pharma
Antisoma
Anza Therapeutics
Aphios
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Ardea Biosciences
Ariad
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Pharmaceuticals
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Avila Therapeutics
Axelar
Bayer
Benitec
Betapharma
Bio-Medisinsk Innovasjon
BioAlliance Pharma
Biogen Idec
Biokine Therapeutics
BioLineRx
Bionovo
BioNTech
BioNumerik
BioSante
Biosceptre
Biotech Ltd
Biotecnol
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
CanBas
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
Chemokine Therapeutics
Chong Kun Dang
Circadian Technologies
CJ Corp
Clavis Pharma
CLL Pharma
CompleGen
Cornerstone Pharmaceuticals
Coronado Biosciences
Cosmo Pharmaceuticals
Critical Outcome Technologies
CritiTech
CSL
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DNAVEC
Dong-A
ECI
EGEN Inc
Eisai
Elara Pharmaceuticals
Eli Lilly
Endocyte
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Esperance Pharmaceuticals
Exelixis
FibroGen
Flamel Technologies
Fresenius
Galapagos
Galectin Therapeutics
Gemin X Biotechnologies
Genmab
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
GlobeImmune
GlycoGenesys
Gradalis
Hanmi
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunovaccine
ImmuPharma
Immutep
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
Innovive
Inotek
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intezyne Technologies
Intracel
Intrexon
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Jennerex Biotherapeutics
Johnson & Johnson
Kadmon
KAEL-GemVax
Kalypsys
Karyon-CTT
Kiadis
Kyowa Hakko Kirin
Leo
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
Marillion Pharmaceuticals
MBiotec
Meda
MediGene
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mirna Therapeutics
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Mycenax
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NewSouth Innovations
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novogen
Oasmia
Oncalis
OncoGenex Pharmaceuticals
OncoMed
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Pacific Biotech
Paladin Labs
PanaGin
Patrys
PBL Therapeutics
Pepscan Therapeutics
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
PhiloGene
Pierre Fabre
Piramal
Pro-Pharmaceuticals
Progen
Progen Pharmaceuticals
ProMetic Life Sciences
Protgen
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Santhera Pharmaceuticals
Sareum
Scancell
Seattle Genetics
ShimodaAtlantic Oncology
Shire
Sigma-Tau
Silence Therapeutics
Simcere Pharmaceuticals
Sirnaomics
Solbec Pharmaceuticals
Spirogen
SRI International
Sunesis
SuperGen
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
Symphogen
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Targa Therapeutics
Targepeutics
Tau Therapeutics
Taxolog
Tekmira Pharmaceuticals
Telik
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Titan Pharmaceuticals
to-BBB
Tolerx
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TriAct Therapeutics
Trion Pharma
UCB
UMN Pharma
Valeant
Vaxon Biotech
VaxOnco
VBL Therapeutics
Vectura
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
ViroMed
WntResearch
Wyeth
Xerion
Xoma
Yakult Honsha
YM BioSciences
York Pharma
Zeria
Zhejiang Beta Pharma
Zivena
A Shortlist of Drugs Included are:
AEB071
AEG-35156
afatinib
aflibercept
agatolimod
AGS-1C4D4
aldesleukin
ALT-801
amrubicin hydrochloride
APO-866
apricoxib
ARC-100
ARQ-197
ARRY-438162
astuprotimut-r
Auto TAG vaccine
axitinib
bardoxolone methyl
belagenpumatucel-L
belinostat
belotecan hydrochloride
bevacizumab
BIBF-1120
BMS-663513
BMS-936558
bortezomib
bosutinib
brivanib alaninate
brivudine
Buparlisib
Cabozantinib
canfosfamide hydrochloride
capecitabine
catumaxomab
CB-10-01
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
conatumumab
cositecan
CPI-613
crizotinib
CRLX-101
CT-011
dacomitinib
dalotuzumab
dasatinib
decitabine
denenicokin
denileukin diftitox
dinaciclib
docetaxel
dovitinib lactate
doxorubicin
E-7820
E7449
EMD-273063
emepepimut-S
endostatin
eniluracil
entinostat
enzastaurin hydrochloride
epirubicin
erlotinib
etoposide (1)
etoposide phosphate
everolimus
Exherin
fresolimumab
ganetespib
ganitumab
gefitinib
glembatumumab vedotin
golvatinib
GSK-1120212
GSK-2118436
GV-1001
GVAX
Hi-8 MEL
histamine dihydrochloride
icotinib hydrochloride
imatinib mesilate
IMP-321
INCB-24360
iniparib
interferon
interferon (gamma1b)
interleukin-12
interleukin-2
intetumumab
IPH-1101
ipilimumab
irinotecan
irinotecan hydrochloride
ispinesib mesylate
JX-594
kahalalide F
KD032
L19-IL2
Lambrolizumab
lapatinib ditosylate
LEE-011
lenvatinib
lestaurtinib
LGX818
LipoVIL12
masitinib
MDX-1379
MetXia
MGN-1601
MKC-1
MKC-1106-MT
mocetinostat
MORAb-004
motesanib diphosphate
motexafin gadolinium
nadroparin
necitumumab
nilotinib
nimotuzumab
oblimersen sodium
olaparib
OncoVAX
OTS-102
P-276-00
P276-00
paclitaxel
paclitaxel polyglumex
PancAtak
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
peginterferon alfa-2b
pemetrexed disodium
pentamidine isethionate
perifosine
pimasertib
plitidepsin
poly-ICLC
PX-12
RAF-265
ramucirumab
retaspimycin
Rexin-G
rhIFN-alpha
ridaforolimus
rintatolimod
romidepsin
RX-0201
sagopilone
sargramostim
SCIB-1
selumetinib
siltuximab
sorafenib tosylate
ß-lapachone
sunitinib malate
talactoferrin alfa
talminogene laherparepvec
tegafur + uracil
temsirolimus
tesetaxel
thalidomide
thymalfasin
tigatuzumab
tocilizumab
topotecan
trabedersen
trastuzumab
tremelimumab
triciribine phosphate
TS-1
tucotuzumab celmoleukin
varlitinib
velimogene aliplasmid
veliparib
vemurafenib
verubulin
vinflunine ditartrate
vismodegib
vitespen
volociximab
WX-671
YM-155
Z-360
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Melanoma and Pancreatic Cancer.
    To find out more about Triple Analysis: Lung Cancer, Melanoma and Pancreatic Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Melanoma and Pancreatic Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Melanoma, Prostate Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Learn More


Triple Analysis: Lymphoma, Pancreatic Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Pancreatic Cancer and by the mechanism/target/effect of Angiogenesis. Learn More

Other selected research from the 'Oncology' category:


Apoptosis: Promise or deception?
In this publication, BioSeeker Group analyzes the latest progress made for 25 drug candidates targeting the cell death pathway, apoptosis. Additionally, more early stage candidates are also under investigation, which brings the total number of companies interested in this field to around 40. Learn More


Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Learn More